|
|
||||||||




* Institute of Immunology, Chung Shan Medical University, Taichung 40203, Taiwan, R.O.C;
Department of Health, Executive Yuan, Hua-Lien Hospital, Hua-Lien 97061, Taiwan, R.O.C;
Graduate Institute of Chinese Medical Science, China Medical University, Taichung 40402, Taiwan, R.O.C;
Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40203, Taiwan, R.O.C.; || Institutes of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung 40203, Taiwan, R.O.C.
To whom requests for reprints should be addressed at 1 Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 110 section 1, Chien Kuo N. Road, Taichung 402, Taiwan, R.O.C. E-mail: bstzang{at}csmu.edu.tw
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disorder of unknown etiology. However, the definitive mechanisms remain obscure. Recently, transglutaminase 2 (TG2) was implicated in the pathogenesis of SLE. Cystamine, which inactivates TG2 activity by forming a mixed disulfide, may interfere with and inhibit other thiol-dependent enzymes such as caspases. To investigate the effects of cystamine in SLE pathogenesis, this in vivo study assessed the serum and macrophage response after administration of cystamine to NZB/W F1 mice. The experimental results demonstrated for the first time a significant reduction in TG2 and matrix metalloproteinase (MMP)-9 activity; tissue inhibitor of metalloproteinases (TIMP)-1, TIMP-2, TG2, tumor necrosis factor alpha, and tumor growth factor beta mRNA expression; and anticardiolipin autoantibodies (aCL) in NZB/W F1 mice following cystamine administration. It strongly suggests the therapeutic potential of cystamine in SLE.
Key Words: systemic lupus erythematosus (SLE) matrix metalloproteinase (MMP) transglutaminase 2 (TG2) cystamine
This article has been cited by other articles:
![]() |
N. Shweke, N. Boulos, C. Jouanneau, S. Vandermeersch, G. Melino, J.-C. Dussaule, C. Chatziantoniou, P. Ronco, and J.-J. Boffa Tissue Transglutaminase Contributes to Interstitial Renal Fibrosis by Favoring Accumulation of Fibrillar Collagen through TGF-{beta} Activation and Cell Infiltration Am. J. Pathol., September 1, 2008; 173(3): 631 - 642. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |